A crucial milestone in systemic CRC treatment is represented by the clinical development of targeted agents interfering with growth factor-driven and neo-angiogenic pathways (such as the epidermal growth factor receptor and the vascular endothelial growth factor [VEGF] and its receptor, respectively) and, more recently, immunotherapy [3,4]. This evidence concerns the gene VEGFA and colorectal carcinoma.